Ingersoll Rand Earnings Call Transcripts
Fiscal Year 2026
-
The meeting confirmed quorum, presented four proposals, and saw all director nominees elected, with all proposals—including auditor ratification, executive compensation, and the 2026 Omnibus Incentive Plan—approved. No shareholder questions were raised.
-
Short cycle demand and recurring revenue are strengthening, with prior headwinds from tariffs and China now largely resolved. Margin expansion is expected in the second half, driven by normalized pricing, productivity, and robust M&A activity, especially in life sciences.
-
Q1 2026 saw strong revenue and EPS growth, robust M&A activity, and positive momentum in short-cycle businesses, with guidance reaffirmed for the year. Tariff and Middle East risks are being managed, and life sciences and innovation continue to drive segment outperformance.
-
The company has executed 76 acquisitions since its merger, driving global expansion and recurring revenue growth, with life sciences and precision technologies as key contributors. Regional performance is strong in non-China APAC and India, while prudent guidance and ongoing investments in innovation, AI, and energy efficiency support future growth.
-
Momentum in orders and organic growth is evident across regions, with recurring revenue more than doubling in two years. Margin expansion continues through pricing and productivity, while capital allocation remains focused on bolt-on M&A, especially in core and life sciences segments.
-
Strong revenue growth, margin expansion, and disciplined M&A have driven significant value creation and market outperformance. The life science platform is a key growth area, leveraging recurring consumables, global reach, and cross-portfolio synergies. Margin outlook remains robust, with continued focus on strategic acquisitions and operational excellence.
Fiscal Year 2025
-
Q4 and full-year 2025 saw strong order and revenue growth, robust recurring revenue, and disciplined M&A. 2026 guidance projects modest revenue and EPS growth, with margin pressures from tariffs and investments, but continued strength in life sciences and recurring revenue.
-
Q3 saw strong order growth, resilient margins, and robust capital deployment despite tariff headwinds. Guidance was revised for tariffs and delayed price realization, with muted margin expansion expected in early 2026. Life sciences and innovation remain key growth drivers.
-
M&A remains a core growth driver, with a focus on high-margin, technology-rich bolt-ons and rapid integration. Recurring revenue from service contracts is expanding, targeting $1 billion by 2027. Regional growth is strongest in Europe, India, and underpenetrated markets, while U.S. demand is stable but delayed by tariff uncertainty. Margins are set to improve in the year's second half.
-
Raised full-year guidance on revenue, adjusted EBITDA, and EPS after strong Q2 results, robust backlog, and continued M&A activity. Segment performance was solid, with notable growth in orders and revenue, despite margin pressures from volume and tariffs. Liquidity and balance sheet remain strong.
-
Organic orders grew 3-3.5% in Q1, with stable demand and balanced regional performance. Pricing actions have offset tariffs, and recurring revenue surpassed $300M, with expansion into new regions and products. M&A remains focused on bolt-ons, especially in life sciences, supporting growth and margin expansion.
-
Over five years, the business has transformed through major divestitures and over 65 acquisitions, maintaining resilience amid global disruptions. Q1 saw 3% organic order growth, with recurring revenue models and global expansion driving margin and backlog strength. M&A remains active, with a focus on bolt-ons and integration for future growth.
-
Q1 saw 10% order growth, record free cash flow, and stable demand, with prudent full-year guidance maintained despite positive order momentum and tariff headwinds. Segment performance was mixed, with strong PST growth and ITS recurring revenue gains. Robust M&A activity and capital allocation continue.
-
Q4 results showed stable performance outside China, with 2025 organic growth guided at 1%-3%. Recurring revenue and targeted M&A are key growth drivers, while margin improvement is expected from integration and productivity initiatives. Investor sentiment is neutral to positive.
-
Over five years, the company transformed through divestitures, 60+ acquisitions, and a focus on core technologies, driving margin expansion and global growth. Organic growth is guided at 1%-3%, with strong recurring revenue and a robust M&A pipeline supporting future performance.
Fiscal Year 2024
-
Double-digit adjusted EPS growth and record margins were achieved in 2024, with strong free cash flow and disciplined M&A driving expansion. 2025 guidance calls for 3%-5% revenue growth, stable end markets, and continued margin strength, supported by robust pipelines and ongoing operational execution.
-
Recognized for ESG leadership, 66% of the portfolio now features sustainable attributes, with validated SBTi targets and ambitious new water and decarbonization goals. Strategic acquisitions and innovation drive expansion into high-growth sustainable markets, while recurring revenue and operational excellence reinforce long-term value.
-
M&A remains central, with ILC Dover expanding the life sciences platform and opening new M&A opportunities. Recurring revenue is on track to reach $1 billion by 2027, with global CARE contract adoption. Margins are strong, with further gains expected from bolt-on M&A and recurring revenue.
-
Q3 2024 saw record orders, revenue, and margin expansion, with strong free cash flow and double-digit EPS growth. Guidance for 2024 was slightly reduced due to shipment timing, but order momentum, M&A activity, and backlog remain robust, supporting a positive outlook for 2025.
-
A disciplined M&A strategy, strong ownership culture, and focus on sustainability and digitalization drive robust growth and margin expansion. Life sciences and recurring revenue are key growth areas, with global mega projects and a strong demand engine supporting future performance.
-
Stable market conditions persist with steady order trends and strong demand generation, supported by digital tools and AI. Recent acquisitions and a robust M&A pipeline drive growth, while margin expansion continues across segments. Recurring revenue and service innovations are set to boost profitability.
-
Q2 2024 saw record results with 16% Adjusted EBITDA growth and 22% higher EPS year-over-year, prompting a raised full-year outlook. Recent acquisitions, especially ILC Dover, are driving inorganic growth, while China remains a headwind for organic revenue.
-
Americas lead regional performance, while China remains a headwind. Demand generation and digitalization drive growth, with a robust M&A pipeline and a focus on recurring revenue. Legacy asbestos liabilities were divested, reducing risk and strengthening the balance sheet.